Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 18, 2011

 

 

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-31141   33-0655706

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

780 Memorial Drive, Cambridge, MA   02139
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 453-1000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting of Stockholders of Infinity Pharmaceuticals, Inc. (the “Company”) held on May 18, 2011, our stockholders voted on four matters as follows:

1. The following eleven nominees were elected to the Company’s Board of Directors to serve for a one-year term expiring at the 2012 annual meeting of stockholders:

 

     Votes For      Votes Against      Votes Abstaining      Broker Non-Votes  

Martin Babler

     17,598,901         688,224         2,033         1,680,941   

Anthony B. Evnin, Ph.D.

     17,604,528         684,347         283         1,680,941   

Steven H. Holtzman

     17,630,068         658,457         633         1,680,941   

Eric S. Lander, Ph.D.

     13,157,492         5,131,383         283         1,680,941   

Patrick P. Lee

     17,364,843         921,932         2,383         1,680,941   

Arnold J. Levine, Ph.D.

     17,637,669         649,356         2,133         1,680,941   

Thomas J. Lynch, M.D.

     17,635,992         651,133         2,033         1,680,941   

Adelene Q. Perkins

     17,637,367         649,658         2,133         1,680,941   

Ian F. Smith

     17,371,402         915,623         2,133         1,680,941   

James B. Tananbaum, M.D.

     17,370,261         916,864         2,033         1,680,941   

Michael C. Venuti, Ph.D.

     17,599,576         689,299         283         1,680,941   

2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

 

Votes For

   Votes Against    Votes Abstaining    Broker Non-Votes
17,541,240    727,560    20,358    1,680,941

3. The shareholders recommended, in a non-binding, advisory vote, that future advisory votes on the compensation of the Company’s named executive officers be held every three years.

 

Every 3 Years

   Every 2 Years    Every 1 Year    Abstain
12,534,817    69,405    5,670,145    14,791

After taking into consideration the foregoing voting results and the Board’s prior recommendation in favor of an advisory shareholder vote on the compensation of the Company’s named executive officers every three years, the Board intends to hold future advisory votes on the compensation of the Company’s named executive officers every three years.

4. The selection of Ernst & Young LLP as our independent registered public accounting firm for the current fiscal year was ratified.

 

Votes For

   Votes Against    Votes Abstaining    Broker Non-Votes
19,948,663    17,414    4,022    —  


Item 8.01 Other Events.

On May 19, 2011, we issued a press release announcing clinical development plans for our Hsp90 chaperone inhibitor program including the initiation of a Phase 2 clinical trial of retaspimycin HCl, also known as IPI-504, in combination with docetaxel in patients with non-small cell lung cancer (NSCLC). In addition, we announced top-line results from our Phase 1b clinical trial of retaspimycin HCl in combination with docetaxel in patients with NSCLC. The full text of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) The following exhibit is included in this report:

 

Exhibit No.

 

Description

99.1   Press Release dated May 19, 2011


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INFINITY PHARMACEUTICALS, INC.
Date: May 19, 2011   By:  

/s/ Gerald E. Quirk

    Gerald E. Quirk
    Vice President, Corporate Affairs and General Counsel